Development of a Retinal Ganglion Cell Specific Gene Therapy Using SIRT1 Signaling for Neuro-Protection (Video)
Creator
Ahmara G. Ross; Devin McDougald; Reas Khan; Thu Duong; Kimberly Dine; Puya Aravand; Natalia Tavares; Jean Bennett; Kenneth Shindler
Affiliation
(AR) University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania; (DM) (JB) Center for Advanced Retinal and Ocular Therapeutics, Philadelphia, Pennsylvania; (RK) (RD) (KD) (PA) (NT) (KS) University of Pennsylvania/Ophthalmology, Philadelphia, Pennsylvania
Subject
Optic Neuropathy, Optic Nerve Trauma and Treatment, Orbit/Ocular Pathology, Miscellaneous
Description
Loss of retinal ganglion cells (RGC) can occur by trauma, inflammatory, and ischemia leading to irreversible effects upon vision. Sirtuin 1 (SIRT1) deacetylase has demonstrated therapeutic value in multiple models of optic neuropathy with small molecule biologics. The initial use of gene therapy modestly improved visual outcomes in the EAE-induced mouse model of optic neuritis but with limited effects due to a low transduction rate and lack of cell specificity. Here we investigated the therapeutic potential of RGC specific SIRT1 gene augmentation in a mouse model of optic nerve crush (ONC).
Date
2020-03
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2020 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2020: Scientific Platform Session III
